CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Therapy in men with low-risk to intermediate to high-risk localized prostate cancer who are candidates for, or have opted for, pros...
Nashville, Tennessee, United States and 38 other locations
pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant prostate ...
Phase 1
Nashville, Tennessee, United States and 18 other locations
Assessment of the safety and efficacy of HLD-0915 as monotherapy in patients with metastatic castration resistant prostate cancer (...
Phase 1, Phase 2
Nashville, Tennessee, United States and 4 other locations
Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potentia ...
Phase 1
Nashville, Tennessee, United States and 23 other locations
A Phase 1/2 study to evaluate the safety and efficacy of ARV-766 given by mouth alone or in combination with abiraterone in men with metastatic prostate...
Phase 1, Phase 2
Nashville, Tennessee, United States and 22 other locations
with high-risk and very high-risk localised/locally advanced prostate cancer with a breast cancer gene mutation (BRCAm)....
Phase 3
Nashville, Tennessee, United States and 145 other locations
Evaluate the safety and tolerability of AMG 509 in adult participants and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2...
Phase 1
Nashville, Tennessee, United States and 54 other locations
clinical efficacy in participants with metastatic hormone-sensitive prostate cancer (mHSPC) by progression-free survival.The resear...
Phase 2
Nashville, Tennessee, United States and 31 other locations
plus prednisone in participants with metastatic castration resistant prostate cancer. Prednisolone may be used instead of prednison...
Phase 2, Phase 3
Nashville, Tennessee, United States and 112 other locations
The main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or sec...
Phase 3
Nashville, Tennessee, United States and 99 other locations
Clinical trials
Research sites
Resources
Legal